软组织多部位转移性神经内分泌肿瘤:1例病例报告并文献回顾
Multisite Metastasis Neuroendocrine Neoplasia of Soft Tissue: A Case Report and Literature Review
DOI: 10.12677/ACM.2023.1392075, PDF, HTML, XML, 下载: 190  浏览: 289 
作者: 张雯晴:西安医学院研究生工作部,陕西 西安
关键词: 肿瘤神经内分泌肿瘤不典型类癌软组织肿瘤Tumor Neuroendocrine Neoplasia Atypical Carcinoid Soft Tissue Tumor
摘要: 神经内分泌肿瘤(NEN)起源于神经嵴的神经内分泌细胞,常发生于消化道及肺部,在喉部及软组织中少见。本文报告一例女性患者,其神经内分泌肿瘤出现在喉部、皮肤及皮下软组织等,诊断依靠组织病理学及免疫组织化学检测。完全手术切除对于此类软组织NEN是较好的治疗方式,通常具有良好的预后。
Abstract: The Neuroendocrine Neoplasia (NEN) originated from neural crest of neuroendocrine cells which often occurs in the digestive tract and lungs, rare in the throat and soft tissue. We report a case of a female patient, the neuroendocrine tumor in the throat, skin and subcutaneous tissue. Its diagnosis relies on histopathological and immunohistochemical detection. It is a better treatment to have a surgical excision of the soft tissue completely and often have a good prognosis.
文章引用:张雯晴. 软组织多部位转移性神经内分泌肿瘤:1例病例报告并文献回顾[J]. 临床医学进展, 2023, 13(9): 14833-14838. https://doi.org/10.12677/ACM.2023.1392075

1. 引言

神经内分泌肿瘤(NEN)是起源于神经内分泌细胞的罕见肿瘤。在美国年发病率为6.98/100,000,患病率为170,000 [1] ,国内外研究数据均提示NEN发病率逐渐上升。这些细胞大多是神经嵴起源的,并广泛分布于体内。最常见的NEN是胃肠胰腺系统的NEN (73.7%),其次是气管支气管肺NEN (25.1%) [2] ,也可见于妇科及泌尿道且侵袭性强,复发率高,预后不良 [1] ,然而喉、皮肤及软组织等部位的神经内分泌肿瘤较为少见。NEN在临床上的诊断具有复杂性,除临床症状外,还需包括生物标志物,超声,计算机体层成像(CT),磁共振成像(MRI)等综合诊断。神经内分泌生物标志物对于确诊至关重要,包括突触素、嗜铬粒蛋白A、CD56、CD57、神经元特异性烯醇化酶、突触囊泡蛋白2 (SV2)和蛋白质基因产物9.5 (PGP 9.5) [1] 。NEN的治疗方式包括内镜治疗、外科手术治疗、介入治疗、药物治疗、放疗及肽受体放射性核素治疗(PRRT)等多种手段 [3] 。在本病例中,将介绍本院收治的1例软组织多部位转移性神经内分泌肿瘤的诊疗过程(图1)。

Figure 1. Specific time points corresponding to the diagnostic and therapeutic process

图1. 与诊断和治疗过程相对应的特定时间点

2. 临床资料

患者,女,76岁,以“发现腹部包块4月”之主诉于2023-02-06入院。7年前外院腹部B超示:脐左下实性占位性病变。下腹部CT示:左侧前腹壁占位性病变,转移瘤待排。后感包块缓慢增大,伴局部间断性疼痛。查体:右上腹可见一长约7 cm陈旧性瘢痕。左下腹可触及一大小约7 * 4 cm包块,质硬,活动度差,与周围界限不清,伴压痛。

患者既往7年前于唐都医院行支撑喉镜下喉肿物切除+双侧颈部淋巴结清扫术,术后病理:非典型类癌。1年前于我院行耳廓软骨膜炎清创术 + 耳廓软骨取骨术,术后病理:(左耳屏皮肤)送检皮肤及软骨组织,见神经内分泌肿瘤,结合病史,符合不典型类癌。免疫组化:CK (+)、Vimentin (−)、CgA (+)、Syn (+)、CD56 (−)、LCA (−)、CK5/6 (−)、P40 (−)、P63 (−)、CK20 (−)、CEA (−)、CD117 (−)、TTF-1 (−)、降钙素(−)、S-100 (−)、Ki-67指数约10%。1年前行胆囊切除术。

入院后下腹部MRI平扫(图2(A)、图2(B))示:扫及左腹壁脂肪层内可见类圆形稍长T1等及长T2信号影,其内信号欠均匀,中心可见长T1、长T2信号影,病变界清,大小约4.0 * 4.0 * 3.6 cm (上下径 * 左右径 * 前后径)。浅表B超(图2(C)、图2(D))示:左侧腹壁皮下可探及低回声包块,大小约3.5 * 3.1 * 3.4 cm,边界不清,形态不规则,呈分叶状,内回声欠均匀,内可见条状强回声。

Figure 2. A and B for MRI under T1, T2, tumor location, size and density, etc.; C, D for superficial under ultrasound echoes the left lower abdominal wall bag piece

图2. A、B为MRI下T1、T2相肿块位置、大小及密度等;C、D为浅表B超下左侧腹壁低回声包块

为明确诊断,行腹壁肿物穿刺,病理示:光镜所见:肿瘤细胞呈巢团状排列。(腹壁)送检穿刺组织内见神经内分泌肿瘤,结合病史,符合不典型类癌。免疫组化:CK (+)、Syn (+)、CgA (+)、CD56 (+)、P53突变型表达、Ki-67指数约25%。遂于2023-02-15行腹壁肿瘤扩大切除+筋膜组织瓣成形术,术中探查见肿块位于皮下脂肪组织内,大小约6 * 5 * 5 cm,质硬、与周围界限欠清,完整切除肿块及周围至少1cm正常组织。术后病理回报:光镜所见(图3):肿瘤细胞呈巢状排列。(腹壁)送检皮肤组织,皮下组织内见神经内分泌肿瘤,结合病史,符合不典型类癌。免疫组化:CK (+)、Syn (+)、CgA (+)、CD56部分弱(+)、P53 (+)、SSTR2 (0)、Ki-67指数约15%。患者术后恢复可。考虑到神经内分泌肿瘤常见于胃肠道系统,术后行胃镜(图4)未见明显异常。因患者一般情况稍差,暂未行肠镜,后予以出院。

Figure 3. The tumor cells are arranged in nests under a light microscope

图3. 光镜下肿瘤细胞呈巢状排列

Figure 4. Cardia under gastroscope is not seen obvious abnormity

图4. 胃镜下贲门未见明显异常

3. 讨论

神经内分泌肿瘤(neuroendocrine neoplasms, NENs)起源于全身肽能神经元和神经内分泌细胞,具有神经内分泌功能并表达神经内分泌标志物,可发生于全身各处 [4] ,最常见的NENs发生在胃肠道和呼吸系统 [5] 。喉神经内分泌肿瘤少见,其有4种不同类型,包括副神经节瘤、典型类癌、非典型类癌和小细胞神经内分泌癌 [6] 。而喉不典型类癌属于中分化神经内分泌肿瘤,一直被认为是最多见的喉神经内分泌癌 [7] ,在喉不典型类癌病理学诊断中,平均每10个HPF的有丝分裂数 > 2个 [8] ,同时还需要排除副神经节瘤和甲状腺髓样癌,一般前者细胞角蛋白表达呈阳性,而后者的甲状腺转录因子1 (TTF-1)表达呈阳性 [9] 。喉类癌常见症状是声音嘶哑、吞咽困难和呼吸窘迫 [7] ,其他症状包括喉部异物感,耳痛或耳部放射痛。其可转移至颈淋巴结、皮肤皮下组织、以及远隔部位,发生概率分别为43%、22%、44% [10] 。肿瘤远处皮肤转移并疼痛是喉不典型类癌特殊表现,其他转移部位包括肺、骨、肝脏、心脏、胰腺、脑、胸膜及头皮 [11] [12] 。喉不典型类癌的淋巴结转移率和复发率高,5年生存率约为46%,因此首选手术治疗,包括喉部分切除术和全喉切除术 [13] ,同时还应行颈部淋巴结清扫术,而其术后5年生存率可达67% [14] 。相关研究表明 [15] ,喉不典型类癌的全身治疗建议参考肺部不典型类癌的治疗,建议II/III期病变采用辅助化疗,对于IV期病变,建议进行同步放化疗。本病例中患者首次就诊时,病理诊断为喉不典型类癌,后行手术治疗,术后未接受包括放化疗在内的其他治疗,而Gillenwater [16] 等人的研究中提示,手术联合放化疗或许更有益于预后。

皮肤和软组织的神经内分泌肿瘤通常分为原发性和转移性,原发性皮肤和软组织NET极为罕见,是在排除不同脏器部位的隐匿性肿瘤转移后做出的 [17] ,其中Merkel细胞癌(Merkel cell carcinoma, MCC)是高度恶性的原发性神经内分泌癌,临床罕见 [18] 。而转移性被认为是疾病的晚期表现 [19] [20] 。MCC在临床上多发生于日光照射部位,最常见于头颈部、四肢 [17] ,恶性度极高,主要位于真皮,表现为一个或多个结节,可以侵入皮下组织,周围淋巴管内可见癌栓 [21] 。MCC的诊断主要依靠病理医师,大多数MCC肿瘤细胞大小一致,核圆形、椭圆形,染色质呈胡椒盐样,核仁不明显,细胞质缺乏,大量的核分裂像和核碎屑,坏死明显 [21] 。Merkel细胞癌的治疗需行广泛切除及区域淋巴结清扫术 [22] ,后可行放化疗。大多数原发性皮肤NET是单发的,而转移性通常为多发 [23] 。在鉴别转移性皮肤NET与MCC时,两者神经内分泌标志物如突触素和嗜铬粒蛋白呈阳性可能是共同的。而细胞角蛋白(CK20)有助于区分,在MCC中CK20染色为核旁点状,NET中染色为弥漫胞质 [24] 。

总之,皮肤和软组织的神经内分泌肿瘤较为罕见,目前缺乏足够的临床病例分析,且尚无统一的诊治指南,仍有许多问题有待进一步阐明。在本病例中,首先,对于鉴别原发性及转移性软组织神经内分泌肿瘤,患者1年前耳屏皮肤、软骨组织及本次入院腹壁皮肤、皮下脂肪组织均检出神经内分泌肿瘤,考虑到其既往病史及喉部不典型类癌转移特点,因此倾向于转移性软组织NET。另外,原发性NET的诊断是在排除其他隐匿性内脏肿瘤后作出的。但不足的是,我们尚未完善肠镜、PET-CT等检查对患者全身情况进行进一步评估,进而对疾病作出更准确的诊断。其次,在术后病理免疫组化中,与NET相关的标记物如突触素、嗜铬粒蛋白等我们并未检测。然而,在软组织NET中,可选择的治疗方式是外科手术,在某些情况下可结合区域淋巴结清扫 [25] 。对于不适合手术的患者,还可选择的治疗包括干扰素-α和长效生长抑素类似物、放疗、消融治疗和化疗 [26] [27] 。在我们的病例中,考虑肿块局限于皮下脂肪层,且局部出现疼痛症状,我们最终选择手术切除,术后患者恢复良好。因此,我们希望本病例诊疗过程中出现的问题以及可取之处能对临床医生有所启发。随着临床医生对神经内分泌肿瘤的进一步探索,相信未来会有更多更有效的治疗方案。

参考文献

[1] Virarkar, M., Vulasala, S.S., Morani, A.C., Waters, R., Gopireddy, D.R., Kumar, S., Bhosale, P. and Lall, C. (2022) Neuroendocrine Neoplasms of the Gynecologic Tract. Cancers, 14, Article 1835.
https://doi.org/10.3390/cancers14071835
[2] Modlin, I.M. and Sandor, A. (1997) An Analysis of 8305 Cases of Carcinoid Tumors. Cancer, 79, 813-829.
https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2
[3] 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版) [J/OL]. 中国癌症杂志: 1-36.
https://doi.org/10.19401/j.cnki.1007-3639.2022.06.010, 2023-08-24.
[4] Fang, C., Wang, W., Zhang, Y., Feng, X., Sun, J., Zeng, Y., Chen, Y., Li, Y., Chen, M., Zhou, Z. and Chen, J. (2017) Clinicopathologic Characteristics and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study in South China. Chinese Journal of Cancer, 36, Article No. 51.
https://doi.org/10.1186/s40880-017-0218-3
[5] Rizen, E.N. and Phan, A.T. (2022) Neuroendocrine Tumors: A Relevant Clinical Update. Current Oncology Reports, 24, 703-714.
https://doi.org/10.1007/s11912-022-01217-z
[6] Ferlito, A., Silver, C.E., Bradford, C.R. and Rinaldo, A. (2009) Neuroendocrine Neoplasms of the Larynx: An Overview. Head & Neck, 31, 1634-1646.
https://doi.org/10.1002/hed.21162
[7] Kumar, P.D., Simha, N.V. and Sreenivas, N. (2014) Atypical Carcinoid of Larynx: A Case Study and a Brief Review. Journal of Clinical and Diagnostic Research, 8, KD03-KD04.
[8] 毛泽凡, 陈曦, 程雷. 喉神经内分泌癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 114-119.
[9] Hirsch, M.S., Faquin, W.C. and Krane, J.F. (2004) Thyroid Transcription Factor-1, but Not p53, Is Helpful in Distinguishing Moder-ately Differentiated Neuroendocrine Carcinoma of the Larynx from Medullary Carcinoma of the Thyroid. Modern Pa-thology, 17, 631-636.
https://doi.org/10.1038/modpathol.3800105
[10] Woodruff, J.M. and Senie, R.T. (1991) Atypical Carcinoid Tumor of the Larynx: A Critical Review of the Literature. ORL, 53, 194-209.
https://doi.org/10.1159/000276219
[11] Ferlito, A. and Friedmann, I. (1989) Review of Neuroendocrine Carcino-mas of the Larynx. Annals of Otology, Rhinology & Laryngology, 98, 780-790.
https://doi.org/10.1177/000348948909801006
[12] Ereño, C., Lopez, J.I. and Sanchez, J.M. (1997) Atypical Car-cinoid of Larynx: Presentation with Scalp Metastases. The Journal of Laryngology & Otology, 111, 89-91.
https://doi.org/10.1017/S0022215100136539
[13] Strosberg, C., Ferlito, A., Triantafyllou, A., Gnepp, D.R., Bish-op, J.A., Hellquist, H., Strojan, P., Willems, S.M., Stenman, G., Rinaldo, A. and Hernandez-Prera, J.C. (2019) Update on Neuroendocrine Carcinomas of the Larynx. American Journal of Clinical Pathology, 152, 686-700.
https://doi.org/10.1093/ajcp/aqz106
[14] Modlin, I.M., Lye, K.D. and Kidd, M. (2003) A 5-Decade Analysis of 13,715 Carcinoid Tumors. Cancer, 97, 934-959.
https://doi.org/10.1002/cncr.11105
[15] Pusceddu, S., Lo Russo, G., Macerelli, M., Proto, C., Vitali, M., Signorel-li, D., Ganzinelli, M., Scanagatta, P., Duranti, L., Trama, A., Buzzoni, R., Pelosi, G., Pastorino, U., de Braud, F. and Garassino, M.C. (2016) Diagnosis and Management of Typical and Atypical Lung Carcinoids. Critical Reviews in On-cology/Hematology, 100, 167-176.
https://doi.org/10.1016/j.critrevonc.2016.02.009
[16] Gillenwater, A., Lewin, J., Roberts, D. and El-Naggar, A. (2005) Moderately Differentiated Neuroendocrine Carcinoma (Atypical Carcinoid) of the Larynx: A Clinically Aggres-sive Tumor. Laryngoscope, 115, 1191-1195.
https://doi.org/10.1097/01.MLG.0000166179.40750.1B
[17] Courville, P., Joly, P., Thomine, E., Ziade, J., Sou-brane, J.C., Kuhn, J.M. and Lauret, P. (2000) Primary Cutaneous Carcinoid Tumour. Histopathology, 36, 566-567.
https://doi.org/10.1046/j.1365-2559.2000.00918-2.x
[18] Liang, E., Brower, J.V., Rice, S.R., Buehler, D.G., Saha, S. and Kimple, R.J. (2015) Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience. PLOS ONE, 10, e0129476.
https://doi.org/10.1371/journal.pone.0129476
[19] Jedrych, J., Busam, K., Klimstra, D.S. and Pulitzer, M. (2014) Cutaneous Metastases as an Initial Manifestation of Visceral Well-Differentiated Neuroendocrine Tumor: A Report of Four Cases and a Review of Literature. Journal of Cutaneous Pathology, 41, 113-122.
https://doi.org/10.1111/cup.12263
[20] Zuetenhorst, J.M. and Taal, B.G. (2005) Metastatic Carcinoid Tumors: A Clinical Review. Oncologist, 10, 123-131.
https://doi.org/10.1634/theoncologist.10-2-123
[21] 张玲, 李理, 汪芸, 曾艳, 王小玲. Merkel细胞癌1例临床病理分析及文献复习[J]. 实用癌症杂志, 2021, 36(1): 165-167, 171.
[22] 姜虹, 冯瑞娥. 皮肤原始神经外胚层肿瘤1例报道并文献复习[J]. 诊断病理学杂志, 2003, 10(5): 291-292.
[23] Bart, R.S., Kamino, H., Waisman, J., Lind-ner, A. and Colen, S. (1990) Carcinoid Tumor of Skin: Report of a Possible Primary Case. Journal of the American Academy of Dermatology, 22, 366-370.
https://doi.org/10.1016/0190-9622(90)70050-R
[24] Warner, T.F., Uno, H., Hafez, G.R., Burgess, J., Bolles, C., Lloyd, R.V. and Oka, M. (1983) Merkel Cells and Merkel Cell Tumors Ultrastructure, Immunocytochemistry and Re-view of the Literature. Cancer, 52, 238-245.
https://doi.org/10.1002/1097-0142(19830715)52:2<238::AID-CNCR2820520209>3.0.CO;2-W
[25] MacKenzie, D.N., McCormick, C.S. and Morris, R.J. (2003) Lymph Node Metastasis from a Primary Skin Carcinoid Tumour. Brit-ish Journal of Plastic Surgery, 56, 718-721.
https://doi.org/10.1016/S0007-1226(03)00210-8
[26] Ramage, J.K., Davies, A.H., Ardill, J., Bax, N., Caplin, M., Grossman, A., Hawkins, R., McNicol, A.M., Reed, N., Sutton, R., Thak-ker, R., Aylwin, S., Breen, D., Britton, K., Buchanan, K., Corrie, P., Gillams, A., Lewington, V., McCance, D., Meeran, K., Watkinson, A. and UKNETwork for Neuroendocrine Tumours (2005) Guidelines for the Management of Gastroen-teropancreatic Neuroendocrine (Including Carcinoid) Tumours. Gut, 54, iv1-iv16.
https://doi.org/10.1136/gut.2004.053314
[27] Kos-Kudła, B. (2015) Treatment of Neuroendocrine Tumors: New Recommendations Based on the CLARINET Study. Contemporary Oncology/Współczesna Onkologia, 19, 345-349.
https://doi.org/10.5114/wo.2015.56006